SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.     )*

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)         Venrock Healthcare Capital Partners II, L.P. (“VHCP II”), VHCP Co-Investment Holdings II, LLC (“VHCP Co-Invest II”), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

(2)         Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

(3)         This percentage is calculated based upon 54,960,068 shares of the Issuer’s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

2

(1)         Venrock Healthcare Capital Partners II, L.P. (“VHCP II”), VHCP Co-Investment Holdings II, LLC (“VHCP Co-Invest II”), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

(2)         Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

(3)         This percentage is calculated based upon 54,960,068 shares of the Issuer’s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

3

(1)         Venrock Healthcare Capital Partners II, L.P. (“VHCP II”), VHCP Co-Investment Holdings II, LLC (“VHCP Co-Invest II”), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

(2)         Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

(3)         This percentage is calculated based upon 54,960,068 shares of the Issuer’s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

4

(1)         Venrock Healthcare Capital Partners II, L.P. (“VHCP II”), VHCP Co-Investment Holdings II, LLC (“VHCP Co-Invest II”), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

(2)         Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

(3)         This percentage is calculated based upon 54,960,068 shares of the Issuer’s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

5

(1)         Venrock Healthcare Capital Partners II, L.P. (“VHCP II”), VHCP Co-Investment Holdings II, LLC (“VHCP Co-Invest II”), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

(2)         Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

(3)         This percentage is calculated based upon 54,960,068 shares of the Issuer’s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

6

Introductory Note:  This Schedule 13G is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Invest II”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM” and collectively with VHCP II and VHCP Co-Invest II, the “VHCP II Entities”), Bong Koh and Nimish Shah in respect of shares of common stock of Bellerophon Therapeutics, Inc.

Item 1.

(a)                                 Name of Issuer

Bellerophon Therapeutics, Inc.

(b)                                 Address of Issuer’s Principal Executive Offices

184 Liberty Corner Road, Suite 302

Warren, NJ 07059

Item 2.

(a)                                 Name of Person Filing

Venrock Healthcare Capital Partners II, L.P.

VHCP Co-Investment Holdings II, LLC

VHCP Management II, LLC

Bong Koh

Nimish Shah

(b)                                 Address of Principal Business Office or, if none, Residence

(c)                                  Citizenship

Each of the VHCP II Entities was organized in Delaware.  Bong Koh and Nimish Shah are both United States citizens.

(d)                                 Title of Class of Securities

Common Stock, $0.01 par value

(e)                                  CUSIP Number

078771102

Item 3.                             If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

7

Item 4.                                 Ownership

(a) Amount Beneficially Owned as of October 10, 2017:

(b) Percent of Class as of October 10, 2017:

(c) Number of shares as to which the person has, as of October 10, 2017:

                                                (i) Sole power to vote or to direct the vote   

                                                (ii) Shared power to vote or to direct the vote    

                                                (iii) Sole power to dispose or to direct the disposition of   

                                                (iv) Shared power to dispose or to direct the disposition of   

8

(1)           These shares are owned directly as follows: 2,952,442 shares are owned by VHCP II and 1,196,936 shares are owned by VHCP Co-Invest II.

(2)           This percentage is calculated based upon 54,960,068 shares of the Issuer’s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

Item 5.                                   Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. o

Item 6.                                   Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7.                                   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not Applicable

Item 8.                                   Identification and Classification of Members of the Group

Not Applicable

Item 9.                                   Notice of Dissolution of a Group

Not Applicable

9

Item 10.                            Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated:           October 10, 2017

10

EXHIBITS

A:            Joint Filing Agreement

B:            Power of Attorney for Bong Koh

C:            Power of Attorney for Nimish Shah

11

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Bellerophon Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 10th day of October, 2017.

12

EXHIBIT B

POWER OF ATTORNEY FOR BONG KOH

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris, signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 26th day of January, 2015.

13

EXHIBIT C

POWER OF ATTORNEY FOR NIMISH SHAH

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris, signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 13th day of February, 2017.

14